A citation-based method for searching scientific literature

Gregory P Kalemkerian, Navneet Narula, Erin B Kennedy, William A Biermann, Jessica Donington, Natasha B Leighl, Madelyn Lew, James Pantelas, Suresh S Ramalingam, Martin Reck, Anjali Saqi, Michael Simoff, Navneet Singh, Baskaran Sundaram. J Clin Oncol 2018
Times Cited: 185







List of co-cited articles
759 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
20

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
Christian Rolfo, Philip C Mack, Giorgio V Scagliotti, Paul Baas, Fabrice Barlesi, Trever G Bivona, Roy S Herbst, Tony S Mok, Nir Peled, Robert Pirker,[...]. J Thorac Oncol 2018
228
18

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
17

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
359
15

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
15

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
13

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
291
13

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
12

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
12


NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
David S Ettinger, Dara L Aisner, Douglas E Wood, Wallace Akerley, Jessica Bauman, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico, Thomas J Dilling, Michael Dobelbower,[...]. J Natl Compr Canc Netw 2018
241
11

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Charu Aggarwal, Jeffrey C Thompson, Taylor A Black, Sharyn I Katz, Ryan Fan, Stephanie S Yee, Austin L Chien, Tracey L Evans, Joshua M Bauml, Evan W Alley,[...]. JAMA Oncol 2019
111
11

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group.
Manfred Dietel, Lukas Bubendorf, Anne-Marie C Dingemans, Christophe Dooms, Göran Elmberger, Rosa Calero García, Keith M Kerr, Eric Lim, Fernando López-Ríos, Erik Thunnissen,[...]. Thorax 2016
81
12

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S M E Theelen,[...]. N Engl J Med 2017
10

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
10

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
10


Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.
Jason D Merker, Geoffrey R Oxnard, Carolyn Compton, Maximilian Diehn, Patricia Hurley, Alexander J Lazar, Neal Lindeman, Christina M Lockwood, Alex J Rai, Richard L Schilsky,[...]. J Clin Oncol 2018
329
9

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman,[...]. N Engl J Med 2018
9


Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
797
9

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita,[...]. N Engl J Med 2010
9

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
9

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
865
9

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
306
9

Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices.
Nathan A Pennell, Maria E Arcila, David R Gandara, Howard West. Am Soc Clin Oncol Educ Book 2019
45
20

Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.
Lawrence J Jennings, Maria E Arcila, Christopher Corless, Suzanne Kamel-Reid, Ira M Lubin, John Pfeifer, Robyn L Temple-Smolkin, Karl V Voelkerding, Marina N Nikiforova. J Mol Diagn 2017
221
8

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paul K Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F Berger, Charles M Rudin,[...]. Cancer Discov 2015
353
8

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Esther Conde, Susana Hernandez, Rebeca Martinez, Barbara Angulo, Javier De Castro, Ana Collazo-Lorduy, Beatriz Jimenez, Alfonso Muriel, Jose Luis Mate, Teresa Moran,[...]. J Thorac Oncol 2019
23
34

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
C Marchiò, M Scaltriti, M Ladanyi, A J Iafrate, F Bibeau, M Dietel, J F Hechtman, T Troiani, F López-Rios, J-Y Douillard,[...]. Ann Oncol 2019
83
9

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason Chang, Darragh Halpenny,[...]. Clin Cancer Res 2019
104
8

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
8

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.
Natasha B Leighl, Ray D Page, Victoria M Raymond, Davey B Daniel, Stephen G Divers, Karen L Reckamp, Miguel A Villalona-Calero, Daniel Dix, Justin I Odegaard, Richard B Lanman,[...]. Clin Cancer Res 2019
118
8

Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Alexander Drilon, Lu Wang, Maria E Arcila, Sohail Balasubramanian, Joel R Greenbowe, Jeffrey S Ross, Phil Stephens, Doron Lipson, Vincent A Miller, Mark G Kris,[...]. Clin Cancer Res 2015
145
7

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
7

Integrating liquid biopsies into the management of cancer.
Giulia Siravegna, Silvia Marsoni, Salvatore Siena, Alberto Bardelli. Nat Rev Clin Oncol 2017
692
7

Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
Lukas Bubendorf, Reinhard Büttner, Fouad Al-Dayel, Manfred Dietel, Göran Elmberger, Keith Kerr, Fernando López-Ríos, Antonio Marchetti, Büge Öz, Patrick Pauwels,[...]. Virchows Arch 2016
107
7

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Luis Paz-Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Barbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp,[...]. N Engl J Med 2018
7

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Umberto Malapelle, Clara Mayo de-Las-Casas, Danilo Rocco, Monica Garzon, Pasquale Pisapia, Nuria Jordana-Ariza, Maria Russo, Roberta Sgariglia, Caterina De Luca, Francesco Pepe,[...]. Br J Cancer 2017
66
10

Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples.
Francesco Pepe, Caterina De Luca, Riccardo Smeraglio, Pasquale Pisapia, Roberta Sgariglia, Mariantonia Nacchio, Maria Russo, Nicola Serra, Danilo Rocco, Ciro Battiloro,[...]. J Clin Pathol 2019
22
31

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
818
7

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
7

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Emmet J Jordan, Hyunjae R Kim, Maria E Arcila, David Barron, Debyani Chakravarty, JianJiong Gao, Matthew T Chang, Andy Ni, Ritika Kundra, Philip Jonsson,[...]. Cancer Discov 2017
226
7

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, Rolf Linke, Rafael Rosell, Jesus Corral,[...]. Lancet Oncol 2017
378
7

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, Yi-Long Wu, Luis Paz-Ares, Juergen Wolf, Sarayut L Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu,[...]. Lancet 2017
484
7

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
P Garrido, E Conde, J de Castro, J J Gómez-Román, E Felip, L Pijuan, D Isla, J Sanz, L Paz-Ares, F López-Ríos. Clin Transl Oncol 2020
18
38

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Oliver Gautschi, Julie Milia, Thomas Filleron, Juergen Wolf, David P Carbone, Dwight Owen, Ross Camidge, Vignhesh Narayanan, Robert C Doebele, Benjamin Besse,[...]. J Clin Oncol 2017
150
7

False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.
Yuebi Hu, Bryan C Ulrich, Julianna Supplee, Yanan Kuang, Patrick H Lizotte, Nora B Feeney, Nicolas M Guibert, Mark M Awad, Kwok-Kin Wong, Pasi A Jänne,[...]. Clin Cancer Res 2018
151
6

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.
Geoffrey R Oxnard, Kenneth S Thress, Ryan S Alden, Rachael Lawrance, Cloud P Paweletz, Mireille Cantarini, James Chih-Hsin Yang, J Carl Barrett, Pasi A Jänne. J Clin Oncol 2016
496
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.